ATE336511T1 - Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren - Google Patents

Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren

Info

Publication number
ATE336511T1
ATE336511T1 AT96905369T AT96905369T ATE336511T1 AT E336511 T1 ATE336511 T1 AT E336511T1 AT 96905369 T AT96905369 T AT 96905369T AT 96905369 T AT96905369 T AT 96905369T AT E336511 T1 ATE336511 T1 AT E336511T1
Authority
AT
Austria
Prior art keywords
peptidomimetics
peptides
activate
function
structural similarity
Prior art date
Application number
AT96905369T
Other languages
English (en)
Inventor
Thanos Halazonetis
Wolfgang Hartwig
Original Assignee
Wistar Inst
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst, Bayer Corp filed Critical Wistar Inst
Application granted granted Critical
Publication of ATE336511T1 publication Critical patent/ATE336511T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
AT96905369T 1995-02-16 1996-02-16 Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren ATE336511T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/392,542 US6169073B1 (en) 1995-02-16 1995-02-16 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function

Publications (1)

Publication Number Publication Date
ATE336511T1 true ATE336511T1 (de) 2006-09-15

Family

ID=23550993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96905369T ATE336511T1 (de) 1995-02-16 1996-02-16 Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren

Country Status (10)

Country Link
US (6) US6169073B1 (de)
EP (1) EP0809655B1 (de)
JP (1) JP3980055B2 (de)
KR (1) KR100598744B1 (de)
AT (1) ATE336511T1 (de)
AU (1) AU718963B2 (de)
CA (1) CA2213229C (de)
DE (1) DE69636450T2 (de)
ES (1) ES2271950T3 (de)
WO (1) WO1996025434A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
GB9521544D0 (en) * 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
AU4394697A (en) * 1996-08-13 1998-03-06 Trustees Of Princeton University, The P53 mutant
AU7238098A (en) * 1997-05-15 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6767889B1 (en) * 1998-11-10 2004-07-27 Temple University Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof
AU4486500A (en) * 1999-04-23 2000-11-10 Research Corporation Technologies, Inc. Therapeutic compositions and methods for treating tumors
US6994852B1 (en) * 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
GB0011439D0 (en) * 2000-05-12 2000-06-28 Novartis Res Found Cancer diagnosis and assays for screening
US7196242B2 (en) * 2000-05-16 2007-03-27 The Regents Of The University Of California Methods for identifying novel therapeutics and diagnostics in the p53 pathway
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6989239B2 (en) * 2001-06-20 2006-01-24 R.E.D. Laboratories, N.V./S.A. Methods for diagnosis and treatment of chronic immune diseases
US20050032060A1 (en) * 2001-08-31 2005-02-10 Shishir Shah Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
AU2003205830A1 (en) 2002-01-23 2003-09-02 Mohamed Raafat El-Gewely Molecular libraries
US6916621B2 (en) * 2002-03-27 2005-07-12 Spectral Genomics, Inc. Methods for array-based comparitive binding assays
WO2004019866A2 (en) 2002-08-28 2004-03-11 Immunex Corporation Compositions and methods for treating cardiovascular disease
WO2005002526A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Method and compositions for treatment of viral infections
JP2007500132A (ja) 2003-07-25 2007-01-11 アムジェン インコーポレイテッド Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法
US7109852B2 (en) * 2004-01-28 2006-09-19 Lear Corporation Vehicle occupancy intruder security system
US7772367B2 (en) * 2004-01-30 2010-08-10 The Trustees Of Columbia University In The City Of New York C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
JP2009501237A (ja) * 2005-03-14 2009-01-15 ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 生物活性ｆｕｓ１ペプチドおよびナノ粒子−ポリペプチド複合体
KR100749858B1 (ko) * 2005-08-12 2007-08-16 연세대학교 산학협력단 ｐ53 변이체 및 그의 용도
EP2091959A4 (de) * 2006-11-28 2010-05-05 Alzhyme Pty Ltd Verbesserte peptidzusammensetzung
CA2686827C (en) * 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN109627287A (zh) 2007-02-23 2019-04-16 爱勒让治疗公司 三唑大环系统
EP2508531B1 (de) 2007-03-28 2016-10-19 President and Fellows of Harvard College Geheftete Polypeptide
EP2224961A1 (de) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Kleinmolekülige krebsbehandlungen, die nekrose in krebszellen verursachen, aber normale zellen nicht angreifen
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2376100B1 (de) 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
EP2566499B1 (de) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex
EP3023496B1 (de) 2010-05-13 2020-07-29 Sarepta Therapeutics, Inc. Verbindungen, die die signalaktivität von interleukin-17- und interleukin-23 modulieren
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
JP6116479B2 (ja) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2814514B1 (de) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
RU2693487C2 (ru) 2013-08-07 2019-07-03 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Пептиды, способные реактивировать мутанты р53
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
RU2762089C2 (ru) 2016-02-04 2021-12-15 Иеда Рисеч Энд Девелопмент Ко. Лтд. ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
EP3813867A1 (de) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Behandlung von lymphatischen metastasen
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3860466B1 (de) 2018-10-04 2023-08-09 Koninklijke Philips N.V. Strömungsdetektion für ultraschallabbildungsvorrichtungen, systeme und verfahren
WO2021072056A1 (en) * 2019-10-08 2021-04-15 Portage Glasgow Limited P53 peptide disrupters of f0x04:p53 protein binding, variants and conjugates thereof.
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
EP4412650A1 (de) * 2021-10-05 2024-08-14 The Penn State Research Foundation Verfahren zur behandlung von krebs mit mutiertem p53

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362623A (en) 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
CA2124595A1 (en) 1992-09-30 1994-04-14 Hanswalter Zentgraf Process for detecting p53-specific antibodies
FR2698367B1 (fr) 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
GB9224784D0 (en) 1992-11-26 1993-01-13 Univ Dundee Cellular protein
AU1440695A (en) 1993-12-21 1995-07-10 Sloan-Kettering Institute For Cancer Research P53-based polypeptide fragments, nucleic acid molecules encoding same, and uses thereof
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function

Also Published As

Publication number Publication date
US6245886B1 (en) 2001-06-12
KR100598744B1 (ko) 2006-09-22
US6169073B1 (en) 2001-01-02
DE69636450D1 (de) 2006-09-28
JP3980055B2 (ja) 2007-09-19
WO1996025434A1 (en) 1996-08-22
DE69636450T2 (de) 2007-05-03
EP0809655A1 (de) 1997-12-03
CA2213229A1 (en) 1996-08-22
KR19980702283A (ko) 1998-07-15
US7666983B2 (en) 2010-02-23
US20030171537A1 (en) 2003-09-11
US20030124557A1 (en) 2003-07-03
US7189801B2 (en) 2007-03-13
ES2271950T3 (es) 2007-04-16
US6784157B2 (en) 2004-08-31
CA2213229C (en) 2014-10-14
AU4915096A (en) 1996-09-04
JPH11500311A (ja) 1999-01-12
US6420118B1 (en) 2002-07-16
EP0809655B1 (de) 2006-08-16
US20070167611A1 (en) 2007-07-19
AU718963B2 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
DE69636450D1 (de) PEPTIDE UND PEPTIDOMIMETIKA MIT STRUKTURELLER ÄHNLICHKEIT MIT p53 UND DIE DIE p53-FUNKTION AKTIVIEREN
EP0832973A3 (de) GTP-bindende Proteine
AU676859B2 (en) Synthetic peptides, antibodies against them and their use
GR3034332T3 (en) Protein purification.
BG103522A (en) Compositions and methods for ob type protein syntheses
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
AU5229498A (en) Mutants of the lag-3 proteins, products for the expression of these mutants and use
ATE397062T1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
ZA965565B (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
ES2172044T3 (es) Supresion de la proliferacion de celulas t usando fragmentos peptidicos de proteina basica de mielina.
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
MXPA03006218A (es) Receptor de citosina tipo 2 y acidos nucleicos que codifican para lo mismo.
DE69333952D1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
AU7216498A (en) Inhibitors of the urokinase receptor
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
EP0780472A3 (de) Stress Proteine
DE68914397D1 (de) Menschliches Lymphotoxin.
WO1999031229A3 (en) Peptides and nucleic acids derived from eisenia foetida and the use thereof
WO2000070046A3 (en) Secreted polypeptides and corresponding polynucleotides
CA2140091A1 (en) Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties